Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 7/20 | 0.40 |
| ▸ | MMP2 | P08253 | 6/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 8/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366554 | 1.00 | ADAM10 (0.40) | ADAM10MMP2MMP9MMP3CDK9 | |
| SCHEMBL1365377 | 0.89 | ADAM10 (0.44) | ADAM10MMP2MMP9MMP3ENPP2 | |
| SCHEMBL1364579 | 0.89 | ADAM10 (0.44) | ADAM10MMP2MMP9MMP3CDK9 | |
| SCHEMBL4328307 | 0.86 | ADAM10 (0.56) | ADAM10MMP2MMP9MMP3ERBB2 | |
| SCHEMBL1363710 | 0.81 | ADAM10 (0.58) | ADAM10MMP2MMP9MMP3CDK9 | |
| SCHEMBL1366551 | 0.81 | ADAM10 (0.58) | ADAM10MMP2MMP9MMP3CDK9 | |
| SCHEMBL1365372 | 0.79 | ADAM10 (0.65) | ADAM10MMP2MMP9MMP3ENPP2 | |
| SCHEMBL1364487 | 0.79 | ADAM10 (0.65) | ADAM10MMP2MMP9MMP3ENPP2 | |
| SCHEMBL1367331 | 0.77 | ADAM10 (0.42) | ADAM10MMP2MMP9MMP3ENPP2 | |
| SCHEMBL1365261 | 0.76 | ADAM10 (0.53) | ADAM10MMP2MMP9MMP3ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020402-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Holdings Corporation (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.